Poll

How do you manage patients with refractory OAB?

Usually refer to another urologist for InterStim
Usually refer to another urologist for PTNS
Usually refer to another urologist for onabotulinumA (Botox)
Usually manage myself
Other
Related Videos
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Considerations for patient follow-up after onabotA administration
Administering onabotA: Improving patient comfort and easing anxiety
Administering onabotA: Improving patient comfort and easing anxiety
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
Experts discuss expanding use of vibegron for OAB
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
Optimizing onabotA for OAB: What are some common misconceptions?
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
Investigators characterize vibegron prescribing patterns for OAB
Colin Goudelocke, MD, answers a question during a Zoom video interview
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Related Content
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
May 9th 2025

Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI
April 24th 2025

First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI

Hannah Clarke
"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.
Neuromodulation device shows promising efficacy for neurogenic bladder
April 16th 2025

Neuromodulation device shows promising efficacy for neurogenic bladder

Hannah Clarke
Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
© 2025 MJH Life Sciences

All rights reserved.